Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Binimetinib + Trifluridine-tipiracil hydrochloride |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | colorectal cancer | sensitive | Binimetinib + Trifluridine-tipiracil hydrochloride | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Mektovi (binimetinib) enhanced the efficacy of Lonsurf (trifluridine/tipiracil hydrochloride) treatment and synergistically inhibited proliferation in colorectal cancer cells harboring BRAF V600E in culture (PMID: 28551618). | 28551618 |
PubMed Id | Reference Title | Details |
---|---|---|
(28551618) | MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. | Full reference... |